Customer concentration
Most revenue comes from a very small number of partners, so loss or delay from one partner can materially reduce revenue.
- Scope
- Novartis Gene Therapies and Nippon Shinyaku
- Materiality
- high
REGENXBIO Inc.
REGENXBIO Inc. is a U.S.-based biotechnology company focused on adeno-associated virus (AAV) gene therapy. It develops and licenses its NAV Technology Platform and related gene therapy programs, while also earning royalties and collaboration revenue from partnered products and services.
−85,4 %
−113,8 %
+104,5 %
2.38
2.38
| % | |
|---|---|
| Platform licensing | 55% Licenses of the NAV Technology Platform and related intellectual property to biotech and pharma partners. |
| Royalties | 35% Royalty income tied mainly to sales of partnered gene therapy products such as Zolgensma and Itvisma. |
| Collaboration services | 10% Development, manufacturing, and other service work performed under collaboration agreements. |
REGENXBIO sells primarily to a small number of biotechnology and pharmaceutical collaboration partners rather than to...
- Biopharma licenseesprimary
Companies licensing NAV Technology Platform rights for internal R&D and therapeutic development.
- Commercial partnersprimary
Partners that market licensed products and generate royalty streams for REGENXBIO.
- Collaboration partnerssecondary
Partners paying for development, manufacturing, and service work under collaboration agreements.
REGENXBIO is headquartered in Rockville, Maryland, and operates as a U.S.-based company...
- •Headquartered in Rockville, Maryland, United States
- •Revenue depends on partner commercialization across multiple territories
- •Royalty exposure is linked to global sales of licensed products
- •Manufacturing and development capabilities support clinical supply needs
- •Geography matters because partner sales drive royalty mix
REGENXBIO’s strategy centers on advancing its NAV AAV platform, expanding partnered gene therapy programs, and...
01
Grow NAV platform partnershipsshort-term
Licensing broadens the installed base of programs that can generate upfront, milestone, and royalty economics.
02
Advance proprietary gene therapy candidatesmedium-term
Internal programs provide potential long-term product revenue beyond platform royalties.
03
Support manufacturing scalabilitymedium-term
AAV manufacturing capability is critical for clinical supply, quality, and future commercialization.
The business depends on a small number of partners and on the success of a limited set of gene therapy programs, so...
Clinical development failure
Lead product candidates must prove safety and efficacy in trials before commercialization is possible.
- Scope
- RGX-202, ABBV-RGX-314 and other pipeline programs
- Materiality
- high
Regulatory approval risk
Gene therapy endpoints and follow-up requirements can delay or prevent approval.
- Scope
- All investigational gene therapy programs
- Materiality
- high
Intellectual property risk
The platform depends on patents and third-party license rights that can be challenged or limited.
- Scope
- NAV Technology Platform and licensed IP
- Materiality
- high
Manufacturing and quality risk
AAV vector production must meet clinical and commercial supply requirements with consistent yield and purity.
- Scope
- NAV platform manufacturing processes and assays
- Materiality
- medium
ASC 606 revenue recognition
Can shift revenue between periods and create volatility
Significant financing components
Affects reported interest income from licensing
Royalty monetization liabilities
Influences leverage, cash flow, and earnings presentation
IP and patent-related estimates
Could affect asset carrying values and expense recognition
: 29.4.2026